Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Chief Financial Officer | October 06, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Relay Therapeutics, Inc.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,134 |
Last balance in matching sequence
After 2026-10-06 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-10-06 · Sale · Disposed 17,511 · Balance 105,340 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2: This transaction was executed in multiple trades at prices ranging from $18.20 to $19.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 6,538 shares underlying restricted stock units. Row 2 · 2026-10-06 · Sale · Disposed 206 · Balance 105,134 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F4: This transaction was executed in multiple trades at prices ranging from $19.20 to $19.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 6,538 shares underlying restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $18.20 to $19.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 6,538 shares underlying restricted stock units.
F4: This transaction was executed in multiple trades at prices ranging from $19.20 to $19.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 27, 2024 Filed Jul 1, 2024 20:41 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 9,078 | $6.24 | $56,646.72 |
DisclosureSEC source: 0000950170-24-079689 · ownership.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 330,430 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $6.12 to $6.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 304,929 shares underlying RSUs. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 20:41 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 295 | $6.26 | $1,846.70 |
DisclosureSEC source: 0000950170-24-079689 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,508 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on June 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 304,929 shares underlying RSUs. Read SEC document |
| April 29, 2024 Filed Apr 30, 2024 00:31 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,695 | $6.38 | $10,814.10 |
DisclosureSEC source: 0000950170-24-050147 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,803 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,722 shares of restricted stock units ("RSUs") on April 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 305,921 shares underlying RSUs. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 348 | $7.70 | $2,679.60 |
DisclosureSEC source: 0000950170-24-038658 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,498 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on March 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 311,643 shares underlying RSUs. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:11 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 2,005 | $9.64 | $19,328.20 |
DisclosureSEC source: 0001209191-24-002472 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,846 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,724 shares of restricted stock units ("RSUs") on January 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 312,635 shares underlying RSUs. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:16 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001840 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,851 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · balance_after: Includes 318,359 shares underlying RSUs. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 294 | $11.51 | $3,383.94 |
DisclosureSEC source: 0001209191-23-059998 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,851 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on December 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 118,359 shares underlying RSUs. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 20:18 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,697 | $6.03 | $10,232.91 |
DisclosureSEC source: 0001209191-23-054024 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,145 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,723 shares of restricted stock units ("RSUs") on October 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 119,351 shares underlying RSUs. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 20:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 294 | $8.38 | $2,463.72 |
DisclosureSEC source: 0001209191-23-050863 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,842 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on September 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 125,074 shares underlying RSUs. Read SEC document |
| July 28, 2023 Filed Jul 31, 2023 20:50 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,693 | $11.80 | $19,977.40 |
DisclosureSEC source: 0001209191-23-043843 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,136 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,724 shares of restricted stock units ("RSUs") on July 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 126,066 shares underlying RSUs. Read SEC document |
| June 27, 2023 Filed Jun 28, 2023 21:08 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 294 | $12.12 | $3,563.28 |
DisclosureSEC source: 0001209191-23-040061 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,829 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 991 shares of restricted stock units ("RSUs") on June 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 131,790 shares underlying RSUs. Read SEC document |
| April 28, 2023 Filed May 1, 2023 20:31 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 863 | $11.16 | $9,631.08 |
DisclosureSEC source: 0001209191-23-026277 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,272 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,454 shares of restricted stock units ("RSUs") on April 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 136,049 shares underlying RSUs. Read SEC document |
| April 28, 2023 Filed Jun 1, 2023 22:19 UTC Amendment | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 2,012 | $11.16 | $22,453.92 |
DisclosureSEC source: 0001209191-23-033419 · doc4a.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,123 F1 · shares: This amendment is being filed to correct the number of shares sold to cover the reporting person's income tax withholding obligations upon the vesting of 5,722 shares of restricted stock units ("RSUs") on April 27, 2023, which was inadvertently understated in the reporting person's original Form 4. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Due to the error described above, the reporting person's original Form 4 incorrectly reported that the number of shares held by the reporting person was 149,272, including 136,049 shares underlying RSUs. As reported in this amendment, the correct number of shares held by the reporting person is 148,123, including 132,781 shares underlying RSUs. Read SEC document |
| March 27, 2023 Filed Mar 28, 2023 20:50 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 347 | $15.36 | $5,329.92 |
DisclosureSEC source: 0001209191-23-021420 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,135 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on March 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 138,503 shares underlying RSUs. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:23 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 864 | $21.56 | $18,627.84 |
DisclosureSEC source: 0001209191-23-005700 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,482 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,454 shares of restricted stock units ("RSUs") on January 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 139,495 shares underlying RSUs. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:31 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 97,630 | $0.00 Strike: $20.45 | $0.00 |
DisclosureSEC source: 0001209191-23-004125 · doc4.xml · derivative · entry 3 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,630 Underlying: Common Stock · 97,630 shares Expires 2033-01-16 F4 · derivative.exercise_date: Such option was granted pursuant to the terms of the Issuer's 2020 Stock Option and Incentive Plan and becomes exercisable, if at all, in twelve equal quarterly installments if the last quoted trading price per share of the Issuer's common stock on the Nasdaq Global Market during any fifteen consecutive calendar day period is at least $35.00; provided that the reporting person maintains a service relationship with the Issuer. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:31 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 104,600 | $0.00 Strike: $20.45 | $0.00 |
DisclosureSEC source: 0001209191-23-004125 · doc4.xml · derivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,600 Underlying: Common Stock · 104,600 shares Expires 2033-01-16 F3 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 17, 2023, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:31 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 101,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004125 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,346 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · balance_after: Includes 141,949 shares underlying RSUs. Read SEC document |
| December 27, 2022 Filed Dec 28, 2022 21:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 445 | $14.49 | $6,448.05 |
DisclosureSEC source: 0001209191-22-062827 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,231 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on December 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 40,834 shares underlying RSUs. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 22:01 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,099 | $21.54 | $23,672.46 |
DisclosureSEC source: 0001209191-22-055119 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,676 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,455 shares of restricted stock units ("RSUs") on October 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 41,826 shares underlying RSUs. Read SEC document |
| September 27, 2022 Filed Sep 29, 2022 21:10 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 443 | $22.73 | $10,069.39 |
DisclosureSEC source: 0001209191-22-051544 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,775 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on September 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 44,281 shares underlying RSUs. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 00:26 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,257 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-049244 · doc4.xml · derivative · entry 3 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,257 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 9, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 00:26 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 26,257 | $30.00 | $787,710.00 |
DisclosureSEC source: 0001209191-22-049244 · doc4.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,218 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. F2 · balance_after: Includes 45,273 shares underlying restricted stock units. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 00:26 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 26,257 | $4.12 | $108,178.84 |
DisclosureSEC source: 0001209191-22-049244 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. F2 · balance_after: Includes 45,273 shares underlying restricted stock units. Read SEC document |
| July 28, 2022 Filed Jul 29, 2022 20:53 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 734 | $21.26 | $15,604.84 |
DisclosureSEC source: 0001209191-22-043541 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,218 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,454 shares of restricted stock units ("RSUs") on July 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 45,273 shares underlying RSUs. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 21:59 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 300 | $20.31 | $6,093.00 |
DisclosureSEC source: 0001209191-22-039659 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,952 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on June 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 47,727 shares underlying RSUs. Read SEC document |
| April 28, 2022 Filed May 3, 2022 00:07 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 725 | $25.57 | $18,538.25 |
DisclosureSEC source: 0001209191-22-026522 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,252 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,454 shares of restricted stock units ("RSUs") on April 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 48,719 shares underlying RSUs. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 21:45 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 282 | $29.87 | $8,423.34 |
DisclosureSEC source: 0001209191-22-021828 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,977 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on March 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 51,173 shares underlying RSUs. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:18 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,286 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-021390 · doc4.xml · derivative · entry 3 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,257 Underlying: Common Stock · 13,286 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 9, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:18 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 13,286 | $30.00 | $398,580.00 |
DisclosureSEC source: 0001209191-22-021390 · doc4.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,259 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 52,165 shares underlying RSUs. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:18 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 13,286 | $4.12 | $54,738.32 |
DisclosureSEC source: 0001209191-22-021390 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. F2 · balance_after: Includes 52,165 shares underlying RSUs. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:21 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 78,540 | $0.00 Strike: $20.38 | $0.00 |
DisclosureSEC source: 0001209191-22-005669 · doc4.xml · derivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,540 Underlying: Common Stock · 78,540 shares Expires 2032-01-26 F3 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:21 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 39,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005669 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,259 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. The RSUs shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date. F2 · balance_after: Includes 52,165 shares underlying RSUs. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 00:43 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 295 | $33.10 | $9,764.50 |
DisclosureSEC source: 0001209191-21-071314 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,989 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on December 26, 2021. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 12,895 shares underlying RSUs. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 00:14 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-21-064892 · doc4.xml · derivative · entry 3 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,543 Underlying: Common Stock · 22,500 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 9, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 00:14 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 22,500 | $35.40 | $796,500.00 |
DisclosureSEC source: 0001209191-21-064892 · doc4.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,284 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 13,887 shares underlying RSUs. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 00:14 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 22,500 | $4.12 | $92,700.00 |
DisclosureSEC source: 0001209191-21-064892 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. F2 · balance_after: Includes 13,887 shares underlying RSUs. Read SEC document |
| September 27, 2021 Filed Sep 28, 2021 01:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 293 | $36.87 | $10,802.91 |
DisclosureSEC source: 0001209191-21-057862 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,284 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on September 26, 2021. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 13,887 shares underlying RSUs. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 00:24 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-21-055783 · doc4.xml · derivative · entry 3 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,043 Underlying: Common Stock · 22,500 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 9, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 00:24 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 22,500 | $35.00 | $787,500.00 |
DisclosureSEC source: 0001209191-21-055783 · doc4.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,577 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 00:24 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 22,500 | $4.12 | $92,700.00 |
DisclosureSEC source: 0001209191-21-055783 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:26 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 293 | $35.81 | $10,492.33 |
DisclosureSEC source: 0001209191-21-044063 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,577 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 991 shares of restricted stock units ("RSUs") on June 26, 2021. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 14,879 shares underlying RSUs. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:35 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-21-039325 · doc4.xml · derivative · entry 3 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,543 Underlying: Common Stock · 22,500 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 9, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:35 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 22,500 | $35.00 | $787,500.00 |
DisclosureSEC source: 0001209191-21-039325 · doc4.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,870 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:35 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 22,500 | $4.12 | $92,700.00 |
DisclosureSEC source: 0001209191-21-039325 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 23:37 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-21-024288 · doc4.xml · derivative · entry 3 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,043 Underlying: Common Stock · 22,500 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 9, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 23:37 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 22,500 | $35.00 | $787,500.00 |
DisclosureSEC source: 0001209191-21-024288 · doc4.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 23:37 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 22,500 | $4.12 | $92,700.00 |
DisclosureSEC source: 0001209191-21-024288 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. Read SEC document |
| March 30, 2021 Filed Jun 10, 2021 00:33 UTC Amendment | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-21-039322 · doc4a.xml · derivative · entry 3 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,043 Underlying: Common Stock · 22,500 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 9, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 30, 2021 Filed Jun 10, 2021 00:33 UTC Amendment | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 22,500 | $35.00 | $787,500.00 |
DisclosureSEC source: 0001209191-21-039322 · doc4a.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,870 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.